Raymond James Financial Services Advisors Inc. lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) by 26.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 26,280 shares of the company’s stock after buying an additional 5,498 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in CRISPR Therapeutics were worth $1,717,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Country Trust Bank purchased a new stake in shares of CRISPR Therapeutics in the third quarter worth about $33,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in CRISPR Therapeutics by 159.2% during the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 635 shares of the company’s stock worth $39,000 after purchasing an additional 390 shares in the last quarter. Allworth Financial LP boosted its position in CRISPR Therapeutics by 21.0% during the second quarter. Allworth Financial LP now owns 737 shares of the company’s stock worth $45,000 after purchasing an additional 128 shares in the last quarter. Pinnacle Holdings LLC purchased a new position in CRISPR Therapeutics during the first quarter worth approximately $48,000. Finally, Twin Lakes Capital Management LLC purchased a new position in CRISPR Therapeutics during the third quarter worth approximately $50,000. Hedge funds and other institutional investors own 71.51% of the company’s stock.
CRISPR Therapeutics Stock Down 2.4 %
CRSP stock opened at $50.55 on Thursday. The business has a fifty day moving average of $50.01 and a two-hundred day moving average of $61.26. The stock has a market cap of $3.96 billion, a price-to-earnings ratio of -5.74 and a beta of 1.77. CRISPR Therapeutics AG has a 52-week low of $38.94 and a 52-week high of $86.95.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on CRSP. Citigroup lowered their price target on CRISPR Therapeutics from $83.00 to $63.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 23rd. Royal Bank of Canada lowered their price target on CRISPR Therapeutics from $79.00 to $70.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 2nd. Credit Suisse Group lowered their price target on CRISPR Therapeutics from $90.00 to $78.00 in a research report on Wednesday, November 2nd. SVB Leerink raised their target price on CRISPR Therapeutics from $75.00 to $76.00 and gave the company an “outperform” rating in a research report on Monday, November 7th. Finally, EF Hutton Acquisition Co. I began coverage on CRISPR Therapeutics in a research report on Thursday, January 5th. They issued a “buy” rating and a $75.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and an average price target of $99.88.
Insiders Place Their Bets
In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the firm’s stock in a transaction on Wednesday, December 28th. The stock was sold at an average price of $40.93, for a total transaction of $1,023,250.00. Following the completion of the sale, the chief executive officer now owns 369,111 shares of the company’s stock, valued at $15,107,713.23. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold a total of 75,000 shares of company stock valued at $3,744,250 over the last quarter. 5.30% of the stock is owned by insiders.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.